drugset / Trial / NCT01551628
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Phase 1
Terminated
1 enrolled
Bio-Cancer Treatment International Limited
The University of Hong Kong · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Recombinant Human Arginase 1 (rhArg1)is safe and effective in the treatment of patients with Relapsed or Refractory Leukemia or Lymphoma.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-05
- Completion
- 2013-05
Outcome
Outcome not reported
Stopped (Enrollment): “slow patient recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant human arginase 1 | Protein / enzyme biologic | 1600 iu/kg | Intravenous |